Skip to content
DataLookout
Start free
Menu

NCT05007093

Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib

StatusUnknown
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
  2. Primary completion date changed from estimate of Dec 7, 2023 to Nov 1, 2024
    • Study completion date: Dec 7, 2023 to Jun 30, 2025
    v4
  3. Eligibility criteria expanded, about 124 words
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 10 to confirmed 20
    • Site details revised
    v3
  4. Primary and study completion dates pushed to Dec 7, 2023v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The changes in glucose metabolism
Timeframe: up to 24 months

Secondary (2)

Time to response (TTR)
PFS

Arms and interventions

Anlotinib hydrochlorideExperimental

12 mg, 2 weeks on/ 1 week off, 21 days per cycle; treatment interruption or reduction (to 10 mg or 8 mg) was allowed

Drugs: Anlotinib hydrochloride

Sites

1 site in 1 country

  • Peking Union Medical College HospitalBeijing, China